Sumitomo Life Insurance Co. raised its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 25.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,314 shares of the company’s stock after buying an additional 3,954 shares during the period. Sumitomo Life Insurance Co.’s holdings in AbbVie were worth $4,413,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Wealthspire Advisors LLC increased its holdings in AbbVie by 16.0% during the fourth quarter. Wealthspire Advisors LLC now owns 58,434 shares of the company’s stock valued at $13,352,000 after buying an additional 8,053 shares during the last quarter. Tillman Hartley LLC increased its holdings in AbbVie by 3.6% during the fourth quarter. Tillman Hartley LLC now owns 3,496 shares of the company’s stock valued at $799,000 after buying an additional 121 shares during the last quarter. Allianz SE increased its holdings in AbbVie by 2.7% during the fourth quarter. Allianz SE now owns 97,245 shares of the company’s stock valued at $22,220,000 after buying an additional 2,596 shares during the last quarter. Macquarie Group Ltd. increased its holdings in AbbVie by 5.5% during the fourth quarter. Macquarie Group Ltd. now owns 986,044 shares of the company’s stock valued at $224,893,000 after buying an additional 51,559 shares during the last quarter. Finally, Gerber Kawasaki Wealth & Investment Management increased its holdings in AbbVie by 4.1% during the fourth quarter. Gerber Kawasaki Wealth & Investment Management now owns 4,726 shares of the company’s stock valued at $1,080,000 after buying an additional 184 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.
AbbVie Stock Performance
Shares of NYSE:ABBV opened at $227.54 on Friday. The firm has a fifty day moving average price of $211.05 and a 200 day moving average price of $219.07. AbbVie Inc. has a fifty-two week low of $181.73 and a fifty-two week high of $244.81. The firm has a market cap of $402.02 billion, a price-to-earnings ratio of 112.09, a P/E/G ratio of 0.69 and a beta of 0.32.
Trending Headlines about AbbVie
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: AbbVie said nine-year CLL14 data showed venetoclax plus obinutuzumab delivered durable progression-free survival in previously untreated chronic lymphocytic leukemia, strengthening the case for the drug’s long-term commercial value. AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
- Positive Sentiment: Investors are also focused on AbbVie’s broader pipeline and franchise strength, with commentary pointing to Skyrizi and Rinvoq continuing to drive revenue growth, which supports the company’s outlook beyond legacy Humira. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
- Neutral Sentiment: Several market commentaries described AbbVie as a defensive, high-quality compounder, but noted the shares may not be cheap at current levels, which suggests valuation may temper upside even with strong fundamentals. AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy
- Negative Sentiment: One article highlighted regulatory risk around AbbVie’s fast-acting neurotoxin TrenibotE after an FDA complete response letter, which could delay a potential growth driver if development setbacks persist. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means
Analysts Set New Price Targets
A number of brokerages have commented on ABBV. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Monday. Royal Bank Of Canada assumed coverage on shares of AbbVie in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price objective for the company. Evercore set a $235.00 price objective on shares of AbbVie in a research note on Friday, May 15th. Canaccord Genuity Group increased their price objective on shares of AbbVie from $262.00 to $265.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Finally, William Blair reissued an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and a consensus target price of $253.43.
Check Out Our Latest Research Report on ABBV
AbbVie Company Profile
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Featured Articles
- Five stocks we like better than AbbVie
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
